Fasudil Rho Kinase Inhibition for Slowing Sporadic ALS Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sporadic amyotrophic lateral sclerosis (ALS) are inadequate, particularly for non-familial cases, as existing animal models and therapies do not accurately replicate human ALS pathology, and there is a lack of effective therapies showing benefit in humans beyond safety assessments.
Innovation Solution
Oral administration of fasudil hydrochloride hemihydrate, a rho kinase inhibitor, at doses between 180 to 240 mg per day, is used to treat sporadic ALS, targeting TDP-43-associated pathology and potentially stabilizing or reducing the progression of the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing animal models and therapies are used for sporadic ALS, then safety assessments can be performed, but effective treatment benefits are not achieved in human patients
Solution Approach 1:
The patent changes the dosage parameter of fasudil to 180-240 mg per day, which is significantly higher than previously used doses in animal models or other conditions. This parameter change appears to be the key difference that enables effective treatment of sporadic ALS in humans, resolving the contradiction between safety assessment and effective treatment benefit
Solution Approach 2:
The patent applies fasudil, originally developed for other conditions, to treat sporadic ALS. This multi-functional application of an existing drug to a different disease indication allows the therapy to address sporadic ALS specifically, rather than being limited to familial cases or animal models only
2Reliability
If fasudil is administered at lower doses as previously used in animal models, then safety is maintained, but disease progression is not effectively slowed
Solution Approach 1:
The patent explicitly changes the dosage parameter from lower doses used in animal models to a higher range of 180-240 mg per day for human patients with sporadic ALS. This parameter change is necessary to achieve effective disease progression slowing while the patent maintains that this dosage has been shown to be safe in human patients
3Ease of operation
If existing therapies are applied to sporadic ALS, then treatment can be provided, but the therapies do not accurately replicate human ALS pathology
Solution Approach 1:
The patent identifies that the dosage parameter was incorrectly set based on animal model data rather than human clinical needs. By changing the dosage to 180-240 mg per day based on human patient requirements, the treatment accurately addresses human sporadic ALS pathology rather than simply translating animal model results
Solution Approach 2:
The patent moves from copying animal model dosing regimens to using human-specific dosing parameters. Instead of scaling down from animal models, the treatment is optimized for human physiology and sporadic ALS pathology, creating an accurate human-specific treatment protocol
Data Source
AI summary
The present invention relates to the treatment of a sporadic ALS patient with oral fausdil at a dose of 180-240 mg/day. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.